JANX
Janux Therapeutics IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$908.22M
P/E Ratio
—
EPS
$-1.83
Beta
2.81
52W High
$35.34
52W Low
$12.12
50-Day MA
$13.74
200-Day MA
$20.65
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Janux Therapeutics Inc
Janux Therapeutics, Inc., a biopharmaceutical company, develops therapies based on the patented Tumor Activated T Cell Engager (TRACTr) platform technology to treat cancer patients. The company is headquartered in La Jolla, California.
Fundamentals
| Revenue (TTM) | $10.00M |
| Gross Profit (TTM) | $-115.90M |
| EBITDA | $-155.64M |
| Operating Margin | -1577.00% |
| Return on Equity | -11.50% |
| Return on Assets | -9.55% |
| Revenue/Share (TTM) | $0.16 |
| Book Value | $15.85 |
| Price-to-Book | 0.94 |
| Price-to-Sales (TTM) | 90.82 |
| EV/Revenue | 2.911 |
| EV/EBITDA | -33.80 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 2178.00% |
| Shares Outstanding | $60.83M |
| Float | $41.68M |
| % Insiders | 6.92% |
| % Institutions | 105.01% |
Analyst Ratings
Consensus ($54.00 target)
3
Strong Buy13
Buy1
HoldData last updated: 4/8/2026